Comparative Pharmacology
Head-to-head clinical analysis: OSENI versus SOLIQUA 100 33.
Peer-Reviewed Evidence
Head-to-head clinical analysis: OSENI versus SOLIQUA 100 33.
OSENI vs SOLIQUA 100/33
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
OSENI is a combination of alogliptin (DPP-4 inhibitor) and pioglitazone (PPARγ agonist). Alogliptin increases incretin levels, enhancing glucose-dependent insulin secretion and suppressing glucagon. Pioglitazone improves insulin sensitivity in adipose tissue, liver, and muscle.
SOLIQUA 100/33 is a fixed-ratio combination of insulin glargine and lixisenatide. Insulin glargine is a long-acting basal insulin analog that binds to insulin receptors, promoting cellular glucose uptake and inhibiting hepatic gluconeogenesis. Lixisenatide is a glucagon-like peptide-1 (GLP-1) receptor agonist that potentiates glucose-dependent insulin secretion, suppresses glucagon release, and slows gastric emptying.
1 tablet orally once daily. Each tablet contains alogliptin 12.5 mg and pioglitazone 15 mg, 25 mg, or 30 mg. Maximum daily dose: alogliptin 25 mg/pioglitazone 45 mg.
Subcutaneous injection once daily, initial dose 15 units (insulin glargine equivalent) for patients not previously treated with insulin, with 1 unit per 10g carbohydrate or per 15-30 mg/dL blood glucose elevation.
None Documented
None Documented
Alogliptin: 12.4-21.4 hours; pioglitazone: 3-7 hours; clinical context: allows once-daily dosing.
Lixisenatide: ~3 hours; insulin glargine: ~12-24 hours (depot).
Oseni (alogliptin and pioglitazone): Alogliptin: 60-71% renally excreted unchanged; pioglitazone: 15-30% renally, 60% biliary/fecal.
Renal: ~30% unchanged; biliary/fecal: ~70% as metabolites.
Category C
Category C
Antidiabetic Agent
Antidiabetic Agent